No Data
No Data
Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
The Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 Experts
In the preceding three months, 4 analysts have released ratings for CARISMA Therapeutics (NASDAQ:CARM), presenting a wide array of perspectives from bullish to bearish.The table below provides a snaps
Carisma Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Carisma Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Express News | HC Wainwright & Co. Reiterates Buy on CARISMA Therapeutics, Maintains $8 Price Target
Buy Rating Affirmed for Carisma Therapeutics Amid Progress in CAR-Monocyte Cancer Therapy
No Data